University Hopsital Heidelberg
Heidelberg, 69120, Germany
NCT Number: NCT04454697
The rate of therapy-associated side effects during and after radiotherapy of head and neck tumors is essential. The most effective approach to reducing acute toxicity is to cut out healthy tissue from the radiation field. The distance between the tumor and normal tissue can be individually increased using personalized, 3D printer-based tissue retractors (GWR). Even the smallest geometric changes lead to a significant dose reduction in normal tissue and significant advantages for the patient.
The current randomized phase II study evaluates the use of GWR with regard to acute toxicity. In addition, quality of life, long-term toxicity as well as local control and overall survival 12 months after radiotherapy are evaluated.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Interventional
Not applicable
Heidelberg, 69120, Germany
The most effective approach to reducing acute toxicity after radiotherapy is to cut out healthy tissue from the radiation field. GWR can increase the distance between the tumor and normal tissue. Even the smallest geometric changes lead to a significant dose reduction in normal tissue and significant advantages for the patient. Adequate immobilization also reduces unwanted movements, especially of the tongue.
The GWR are manufactured as combinable modules according to the "modular principle". This improves reproducibility and flexibility and reduces development and manufacturing costs. The study is being conducted as a monocentric, prospective, randomized phase II study. A total of 34 patients who meet the inclusion criteria are examined for acute toxicity after radiotherapy of a malignant head and neck tumor. The primary goal of the study is to reduce acute toxicity through individual immobilization of the jaw and tongue. Secondary study goals are the evaluation of quality of life and long-term toxicity as well as local control and overall survival twelve months after radiotherapy. In both groups, radiation therapy is carried out in accordance with guidelines using image-guided radiotherapy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients receive a tissue retractor to spare healthy tissue during the course of radiation
Time frame: immediately after completin of Radiotherapy
Number of grade III toxcicity events
Time frame: up to 12 month after completion of radiotherapy
Changes of Parameters on the Core Quality of Life Questionnaire C30, scores 1 to 6 (best)
Time frame: up to 12 month after completion of radiotherapy
Changes of Parameters on the Core Quality of Life Questionnaire H&N35, scores 1 to 6 (best)
University Hospital Heidelberg
Other
Geweberetraktoren für Die Strahlentherapie Von Kopf-Hals-Tumoren - Prospektive Randomisierte Phase-II-Studie
Acronym: GUARD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05570851
Alcohol Drinking, Alcohol Use, Unspecified
Manhasset, New York, United States
View Trial DetailsNCT04208490
Head and Neck Cancer, Head and Neck Neoplasms
Kingman, Arizona, United States
View Trial DetailsNCT03117946
Head and Neck Cancer, Head and Neck Neoplasms
Besançon, France
View Trial DetailsNCT00076310
Carcinoma, Carcinoma, Squamous Cell
Houston, Texas, United States
View Trial Details